Skip to main content

Advertisement

SpringerLink
Log in

Optimum Duration of Metastatic Colorectal Cancer Treatment

  • Therapeutic Approaches to Metastatic Colorectal Cancers (E Díaz-Rubio, Section Editor)
  • Published:
Current Colorectal Cancer Reports

Abstract

Optimum duration of treatment depends on the objective of treatment, and should be determined by a multidisciplinary team and in consultation with the patient. Considerations include achieving secondary resectability, pattern of response, adapting treatment intensity to the changing disease, cumulative toxicity, and quality of life. This review discusses available data on these subjects, unanswered questions, and difficulties in interpreting clinical trial data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010. doi:10.1002/ijc.25516.

    Google Scholar 

  3. van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM, Kranse R, et al. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis. 2012;14(1):56–61. doi:10.1111/j.1463-1318.2010.02539.x.

    Article  PubMed  Google Scholar 

  4. Mantke R, Schmidt U, Wolff S, Kube R, Lippert H. Incidence of synchronous liver metastases in patients with colorectal cancer in relationship to clinico-pathologic characteristics. Results of a German prospective multicentre observational study. Eur J Surg Oncol. 2012;38(3):259–65. doi:10.1016/j.ejso.2011.12.013.

    Article  PubMed  CAS  Google Scholar 

  5. Schmoll HJ, Sargent D. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? Lancet. 2007;370(9582):105–7. doi:10.1016/S0140-6736(07)61062-9.

    Article  PubMed  Google Scholar 

  6. Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, et al. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol. 2010;21 Suppl 6:vi1–10. doi:10.1093/annonc/mdq273.

    Article  PubMed  Google Scholar 

  7. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47. doi:10.1016/S1470-2045(09)70330-4.

    Article  PubMed  CAS  Google Scholar 

  8. Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011;12(7):642–53. doi:10.1016/S1470-2045(11)70102-4.

    Article  PubMed  CAS  Google Scholar 

  9. • Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol. 2006;24(3):394–400. doi:10.1200/JCO.2005.03.0106. Historical trial about avoiding oxaliplatin induced neurotoxicity by intermittent oxaliplatin treatment and maintenance.

  10. Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010. doi:10.1245/s10434-010-1166-1.

    Google Scholar 

  11. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–24.

    Google Scholar 

  12. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24(13):2065–72.

    Article  PubMed  CAS  Google Scholar 

  13. Robinson SM, Wilson CH, Burt AD, Manas DM, White SA. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol. 2012;19(13):4287–99. doi:10.1245/s10434-012-2438-8.

    Article  PubMed  Google Scholar 

  14. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243(1):1–7.

    Article  PubMed  Google Scholar 

  15. Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012. doi:10.1093/annonc/mds053 [Epub ahead of print].

    PubMed  Google Scholar 

  16. Suzuki C, Blomqvist L, Sundin A, Jacobsson H, Bystrom P, Berglund A, et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol. 2012;23(4):948–54. doi:10.1093/annonc/mdr350.

    Article  PubMed  CAS  Google Scholar 

  17. Piessevaux H, Schlichting, M. Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer: analysis from the CRYSTAL study. Ann Oncol. 2010;21(8):abstr. 596.

    Google Scholar 

  18. Douillard JY, Siena S, Tabernero J, Peeters M, Davison C. Understanding the value of response and early tumour shinkage (ETS) in pts with wt KRAS mCRC treated with panitumumab plus FOLFOX. Ann Oncol. 2012;23(Suppl 9):ix 190.

  19. Mansmann U, Sartorius U. Deepness of response: a quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC. J Clin Oncol. 2013;30(suppl 34):abstr 427.

  20. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–705. doi:10.1200/JCO.2009.27.4860.

    Article  PubMed  CAS  Google Scholar 

  21. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.

    Article  PubMed  CAS  Google Scholar 

  22. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus Irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–9. doi:10.1200/JCO.2010.33.5091.

    Article  PubMed  Google Scholar 

  23. Cunningham C, Lang I, Lorusso V. Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): results of a randomized international phase III trial (AVEX). J Clin Oncol. 2013;30(suppl 34):abstr 337.

  24. Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E, Wolff RA, et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol. 2011. doi:10.1200/JCO.2010.29.4496.

    Google Scholar 

  25. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27(5):672–80.

    Article  PubMed  CAS  Google Scholar 

  26. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009;27(34):5727–33. doi:10.1200/JCO.2009.23.4344.

    Article  PubMed  CAS  Google Scholar 

  27. • Koopman M, Simkens LH, Ten Tije G-JC. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol. 2013;31(suppl):abstr 3502. Phase III trial defining a new maintenance standard with continuous low dose capecitabine and bevacizumab.

  28. Wasan H, Adams RA. Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): results of the two-arm phase II randomized MRC COIN-b trial. J Clin Oncol. 2012;30(suppl 4):abstr 536.

  29. Diaz-Rubio E, Gomez-Espana A, Massuti B, Sastre J, Abad A, Valladares M, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012;17(1):15–25. doi:10.1634/theoncologist.2011-0249.

    Article  PubMed  CAS  Google Scholar 

  30. Tournigand C, Samson B, Scheithauer W. Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): efficacy and safety results of the international GERCOR DREAM phase III trial. J Clin Oncol. 2012;30(suppl):abstrLBA 3500.

    Google Scholar 

  31. Yalcin S, Uslu R, Dane F. Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): mature data from STOP and GO, a phase III, randomized, multicenter study. J Clin Oncol. 2012;30(suppl):abstr 3565.

  32. Koeberle D, Betticher DC, Von Moos R. Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III noninferiority trial (SAKK 41/06). J Clin Oncol. 2013;31(suppl):abstr 3503.

  33. Grothey A. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. J Clin Oncol. 2008;26(May 20 suppl):abstr 4010.

  34. Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet. 2003;361(9356):457–64.

    Article  PubMed  CAS  Google Scholar 

  35. Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Nicolella D, et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol. 2011;22(5):1236–42. doi:10.1093/annonc/mdq580.

    Article  PubMed  CAS  Google Scholar 

  36. •• Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479–516. doi:10.1093/annonc/mds236. Recent overview of relevant issues for management of localized and metastastic colon and rectal cancer.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Alexander Stein has received payment for lectures including service on speakers’ bureaus from Roche, Merck Serono, Sanofi, Bayer, and Amgen, and has received reimbursement from Roche, Sanofi, Merck Serono, and Amgen for travel, accommodation, and meeting expenses.

Hans-Joachim Schmoll has received compensation from Roche and Sanofi–Aventis for service as a board member; has received compensation from Roche and Bayer for service as a consultant; and has received payment for lectures including service on speakers’ bureaus from Roche.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Hubertus Wald Tumour Center, University Cancer Center Hamburg, Department of Oncology, Hematology, BMT with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Alexander Stein

  2. Department for Oncology/Haematology, Martin Luther University Halle, Wittenberg Ernst Grube Str. 40, 06120, Halle, Germany

    Hans-Joachim Schmoll

Authors
  1. Alexander Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans-Joachim Schmoll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Joachim Schmoll.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stein, A., Schmoll, HJ. Optimum Duration of Metastatic Colorectal Cancer Treatment. Curr Colorectal Cancer Rep 9, 223–229 (2013). https://doi.org/10.1007/s11888-013-0179-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-013-0179-0

Keywords

Search

Navigation